Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E C Keystone

Showing results (1-10 of 128) with videos related to

Pageof 13
Sort By:
The Journal of Rheumatology. Supplement|May 18, 1999
The role of tumor necrosis factor antagonism in clinical practiceE C Keystone
Annals of the Rheumatic Diseases|October 14, 2004
The utility of tumour necrosis factor blockade in orphan diseasesE C Keystone
Rheumatology (Oxford, England)|April 27, 2005
B cells in rheumatoid arthritis: from hypothesis to the clinicE C Keystone
Rheumatic Diseases Clinics of North America|June 9, 2001
Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritisE C Keystone
Clinical and Experimental Rheumatology|November 24, 2004
Safety issues related to emerging therapies for rheumatoid arthritisE C Keystone
Annals of the Rheumatic Diseases|October 9, 2003
Advances in targeted therapy: safety of biological agentsE C Keystone
Canadian Medical Association Journal|July 23, 1977
Biologic role of lymphocytesW Pruzanski, E C Keystone
The Journal of Rheumatology|April 1, 1996
Biologic agents in autoimmune diseasesE C Keystone, V Strand
Arthritis and Rheumatism|November 1, 1981
Hypotension with oliguria: a side-effect of azathioprineE C Keystone, R Schabas
Current Opinion in Rheumatology|February 1, 1992
Infections that cause vasculitisR Mader, E C Keystone
Pageof 13

Showing results (1-10 of 128) with videos related to

Sort By:
Pageof 13
The Journal of Rheumatology. Supplement|May 18, 1999
The role of tumor necrosis factor antagonism in clinical practiceE C Keystone
Annals of the Rheumatic Diseases|October 14, 2004
The utility of tumour necrosis factor blockade in orphan diseasesE C Keystone
Rheumatology (Oxford, England)|April 27, 2005
B cells in rheumatoid arthritis: from hypothesis to the clinicE C Keystone
Rheumatic Diseases Clinics of North America|June 9, 2001
Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritisE C Keystone
Clinical and Experimental Rheumatology|November 24, 2004
Safety issues related to emerging therapies for rheumatoid arthritisE C Keystone
Annals of the Rheumatic Diseases|October 9, 2003
Advances in targeted therapy: safety of biological agentsE C Keystone
Canadian Medical Association Journal|July 23, 1977
Biologic role of lymphocytesW Pruzanski, E C Keystone
The Journal of Rheumatology|April 1, 1996
Biologic agents in autoimmune diseasesE C Keystone, V Strand
Arthritis and Rheumatism|November 1, 1981
Hypotension with oliguria: a side-effect of azathioprineE C Keystone, R Schabas
Current Opinion in Rheumatology|February 1, 1992
Infections that cause vasculitisR Mader, E C Keystone
Pageof 13